Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance

      SARS-CoV-2 antigen tests offer short turnaround time and high specificity but the lower sensitivity relative to nucleic acid testing increases the risk of further transmission by patients with false-negative antigen test results.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Park S.E.
        Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19).
        Clin Exp Pediatr. 2020; 63: 119-124
        • Dutta N.K.
        • Mazumdar K.
        • Gordy J.T.
        The nucleocapsid protein of SARS–CoV-2: a target for vaccine development.
        J Virol. 2020; 94https://doi.org/10.1128/JVI.00647-20
        • Cong Y.
        • Ulasli M.
        • Schepers H.
        • et al.
        Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle.
        J Virol. 2020; 94https://doi.org/10.1128/JVI.01925-19
        • Burbelo P.D.
        • Riedo F.X.
        • Morishima C.
        • et al.
        Detection of nucleocapsid antibody to SARS-CoV-2 is more sensitive than antibody to spike protein in COVID-19 patients.
        J Infect Dis. 2020; https://doi.org/10.1093/infdis/jiaa273
        • Garcia-Beltran W.F.
        • Lam E.C.
        • Astudillo M.G.
        • et al.
        COVID-19-neutralizing antibodies predict disease severity and survival.
        Cell. 2021; 184: 476-488.e11
        • Esbin M.N.
        • Whitney O.N.
        • Chong S.
        • et al.
        Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection.
        RNA. 2020; (rna.076232.120)https://doi.org/10.1261/rna.076232.120
        • Pollock N.R.
        • Jacobs J.R.
        • Tran K.
        • et al.
        Performance and implementation evaluation of the Abbott BinaxNOW Rapid antigen test in a high-throughput drive-through community testing site in Massachusetts.
        J Clin Microbiol. 2021; 59https://doi.org/10.1128/JCM.00083-21
        • Health C for D and R
        EUA Authorized Serology Test Performance. FDA.
        (Available at:) (Accessed June 16, 2021)
        • Hicks J.
        • Klumpp-Thomas C.
        • Kalish H.
        • et al.
        Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses.
        J Clin Immunol. 2021; https://doi.org/10.1007/s10875-021-00997-6
        • Jaimes J.A.
        • André N.M.
        • Chappie J.S.
        • et al.
        Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop.
        J Mol Biol. 2020; 432: 3309-3325
        • Burbelo P.D.
        • Riedo F.X.
        • Morishima C.
        • et al.
        Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019.
        J Infect Dis. 2020; 222: 206-213
        • Gussow A.B.
        • Auslander N.
        • Faure G.
        • et al.
        Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.
        Proc Natl Acad Sci U S A. 2020; 117: 15193-15199
        • Kang S.
        • Yang M.
        • Hong Z.
        • et al.
        Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.
        Acta Pharm Sin B. 2020; 10: 1228-1238
        • Hubbard J.A.
        • Geno K.A.
        • Khan J.
        • et al.
        Comparison of two automated immunoassays for the detection of SARS-CoV-2 nucleocapsid antibodies.
        J Appl Lab Med. 2021; 6: 429-440
        • Poore B.
        • Nerenz R.D.
        • Brodis D.
        • et al.
        A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays.
        Clin Biochem. 2021; https://doi.org/10.1016/j.clinbiochem.2021.05.011
        • Suhandynata R.T.
        • Hoffman M.A.
        • Kelner M.J.
        • et al.
        Multi-platform comparison of SARS-CoV-2 serology assays for the detection of COVID-19.
        J Appl Lab Med. 2020; 5: 1324-1336
        • Tang M.S.
        • Hock K.G.
        • Logsdon N.M.
        • et al.
        Clinical performance of two SARS-CoV-2 serologic assays.
        Clin Chem. 2020; 66: 1055-1062
        • Suhandynata R.T.
        • Hoffman M.A.
        • Huang D.
        • et al.
        Commercial serology assays predict neutralization activity against SARS-CoV-2.
        Clin Chem. 2021; 67: 404-414
        • Tang M.S.
        • Case J.B.
        • Franks C.E.
        • et al.
        Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays.
        Clin Chem. 2020; https://doi.org/10.1093/clinchem/hvaa211
        • Suhandynata R.T.
        • Bevins N.J.
        • Tran J.T.
        • et al.
        SARS-CoV-2 serology status detected by commercialized platforms distinguishes previous infection and vaccination adaptive immune responses.
        medRxiv. 2021; https://doi.org/10.1101/2021.03.10.21253299
        • Guo L.
        • Ren L.
        • Yang S.
        • et al.
        Profiling early humoral response to diagnose novel coronavirus disease (COVID-19).
        Clin Infect Dis. 2020; 71: 778-785
        • Galipeau Y.
        • Greig M.
        • Liu G.
        • et al.
        Humoral responses and serological assays in SARS-CoV-2 infections.
        Front Immunol. 2020; 11https://doi.org/10.3389/fimmu.2020.610688
        • Long Q.-X.
        • Liu B.-Z.
        • Deng H.-J.
        • et al.
        Antibody responses to SARS-CoV-2 in patients with COVID-19.
        Nat Med. 2020; : 1-4https://doi.org/10.1038/s41591-020-0897-1
        • Suhandynata R.T.
        • Hoffman M.A.
        • Kelner M.J.
        • et al.
        Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19.
        J Appl Lab Med. 2020; : jfaa079https://doi.org/10.1093/jalm/jfaa079
        • Long Q.-X.
        • Tang X.-J.
        • Shi Q.-L.
        • et al.
        Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
        Nat Med. 2020; 26: 1200-1204
        • Jiang C.
        • Wang Y.
        • Hu M.
        • et al.
        Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
        Clin Transl Immunology. 2020; 9: e1182
        • Zhao J.
        • Yuan Q.
        • Wang H.
        • et al.
        Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.
        medRxiv. 2020; (2020.03.02.20030189)https://doi.org/10.1101/2020.03.02.20030189
        • Ibarrondo F.J.
        • Fulcher J.A.
        • Goodman-Meza D.
        • et al.
        Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19.
        N Engl J Med. 2020; https://doi.org/10.1056/NEJMc2025179
        • Perreault J.
        • Tremblay T.
        • Fournier M.-J.
        • et al.
        Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset.
        Blood. 2020; 136: 2588-2591
      1. COVID-19 vaccine tracker and landscape.
        (Available at:) (Accessed June 14, 2021)
        • Walsh E.E.
        • Frenck R.W.
        • Falsey A.R.
        • et al.
        Safety and immunogenicity of two RNA-based covid-19 vaccine candidates.
        N Engl J Med. 2020; 383: 2439-2450
        • Anderson E.J.
        • Rouphael N.G.
        • Widge A.T.
        • et al.
        Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults.
        N Engl J Med. 2020; 383: 2427-2438
        • Sadoff J.
        • Le Gars M.
        • Shukarev G.
        • et al.
        Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine.
        N Engl J Med. 2021; https://doi.org/10.1056/NEJMoa2034201
        • Sahin U.
        • Muik A.
        • Derhovanessian E.
        • et al.
        COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
        Nature. 2020; 586: 594-599
        • Mulligan M.J.
        • Lyke K.E.
        • Kitchin N.
        • et al.
        Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
        Nature. 2020; 586: 589-593
        • Feldman R.A.
        • Fuhr R.
        • Smolenov I.
        • et al.
        mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
        Vaccine. 2019; 37: 3326-3334
      2. Covid P-B. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020. 53.

        • Jackson L.A.
        • Anderson E.J.
        • Rouphael N.G.
        • et al.
        An mRNA Vaccine against SARS-CoV-2 — Preliminary report.
        N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2022483
      3. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Announcement - 12/17/2020 - 12/17/2020. FDA.
        (Available at:) (Accessed June 15, 2021)
        • Baden L.R.
        • El Sahly H.M.
        • Essink B.
        • et al.
        Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.
        N Engl J Med. 2021; 384: 403-416
        • Stephenson K.E.
        • Le Gars M.
        • Sadoff J.
        • et al.
        Immunogenicity of the Ad26.COV2.S vaccine for COVID-19.
        JAMA. 2021; 325: 1535-1544
        • Mercado N.B.
        • Zahn R.
        • Wegmann F.
        • et al.
        Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
        Nature. 2020; 586: 583-588https://doi.org/10.1038/s41586-020-2607-z
        • Alter G.
        • Yu J.
        • Liu J.
        • et al.
        Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
        Nature. 2021; https://doi.org/10.1038/s41586-021-03681-2
      4. Covid J. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 202. 62.

      5. CDC. Labs. Centers for Disease Control and Prevention.
        (Available at:) (Accessed June 16, 2021)
        • Perchetti G.A.
        • Huang M.-L.
        • Mills M.G.
        • et al.
        Analytical sensitivity of the Abbott BinaxNOW COVID-19 Ag card.
        J Clin Microbiol. 2021; 59https://doi.org/10.1128/JCM.02880-20
        • Okoye N.C.
        • Barker A.P.
        • Curtis K.
        • et al.
        Performance characteristics of BinaxNOW COVID-19 antigen card for screening asymptomatic individuals in a university setting.
        J Clin Microbiol. 2021; 59https://doi.org/10.1128/JCM.03282-20
        • Prince-Guerra J.L.
        • Almendares O.
        • Nolen L.D.
        • et al.
        Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 Infection at two community-based testing sites - Pima County, Arizona, November 3-17, 2020.
        MMWR Morb Mortal Wkly Rep. 2021; 70: 100-105
        • Pray I.W.
        • Ford L.
        • Cole D.
        • et al.
        Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses - Wisconsin, September-October 2020.
        MMWR Morb Mortal Wkly Rep. 2021; 69: 1642-1647
        • Brihn A.
        • Chang J.
        • OYong K.
        • et al.
        Diagnostic performance of an antigen test with RT-PCR for the detection of SARS-CoV-2 in a hospital setting - Los Angeles County, California, June-August 2020.
        MMWR Morb Mortal Wkly Rep. 2021; 70: 702-706
        • Beck E.T.
        • Paar W.
        • Fojut L.
        • et al.
        Comparison of the Quidel Sofia SARS FIA test to the hologic aptima SARS-CoV-2 TMA test for diagnosis of COVID-19 in symptomatic outpatients.
        J Clin Microbiol. 2021; 59https://doi.org/10.1128/JCM.02727-20
        • Kilic A.
        • Hiestand B.
        • Palavecino E.
        Evaluation of performance of the BD Veritor SARS-CoV-2 chromatographic immunoassay test in patients with symptoms of COVID-19.
        J Clin Microbiol. 2021; 59https://doi.org/10.1128/JCM.00260-21
        • Young S.
        • Taylor S.N.
        • Cammarata C.L.
        • et al.
        Clinical evaluation of BD veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test.
        J Clin Microbiol. 2020; 59https://doi.org/10.1128/JCM.02338-20
        • Moreno G.K.
        • Braun K.M.
        • Pray I.W.
        • et al.
        SARS-CoV-2 transmission in intercollegiate athletics not fully mitigated with daily antigen testing.
        Clin Infect Dis. 2021; https://doi.org/10.1093/cid/ciab343